Helus Pharma Inc., a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), has officially changed its legal name from Cybin Inc. to Helus Pharma Inc., effective October 1, 2026. The change was approved by shareholders at the company's annual and special meeting held on September 22 and follows the adoption of the Helus Pharma business name earlier in January. This legal name change is more than a rebranding exercise; it reflects the company's anticipated transition from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company. For investors and industry observers, the move signals that Helus Pharma is positioning itself for the next phase of growth, potentially bringing its therapies to market and generating revenue.
The company's common shares will continue trading under the ticker HELP on the Nasdaq Global Market and Cboe Canada, with no action required by existing shareholders. This continuity is crucial for maintaining investor confidence and avoiding disruptions in trading. The name change is part of a broader strategic shift as Helus Pharma advances its pipeline of proprietary NSAs designed to activate serotonin pathways and promote neuroplasticity, addressing large unmet needs in depression, anxiety, and other mental health conditions.
Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. These programs underscore the company's potential to deliver durable improvements in mental health. With operations in Canada, the United States, the United Kingdom, and Ireland, Helus Pharma is well-positioned to pursue global commercialization.
The implications of this name change extend to the company's branding and market identity. By aligning its legal name with its commercial operating name, Helus Pharma aims to present a unified front to investors, partners, and patients. This clarity can enhance recognition and trust as the company moves closer to potential product launches. For more details on the name change, visit https://ibn.fm/rrJFh.
MissionIR, a specialized communications platform, has disseminated this news as part of its efforts to enhance visibility for private and public companies. MissionIR is one of over 75 brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. Through these channels, Helus Pharma's strategic rebranding reaches a wide audience of investors and industry stakeholders. For more information about MissionIR, visit MissionIR or www.MissionIR.com. The full terms of use and disclaimers are available at https://www.MissionIR.com/Disclaimer.
